Alembic Pharmaceuticals Ltd (APLLTD)

Alembic Pharmaceuticals manufactures and markets generic pharmaceutical products all over the world. The companys state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Ltd was incorporated on June 16 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in pharmaceuticals business. As per the scheme of arrangement the Pharmaceutical Undertaking of the Alembic Ltd was demerged and transferred to the company with effect from appointed date April 1 2010. In April 15 2011 the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 133515914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement. The shareholding of Alembic Ltd in the company reduced from 100 to 29.18. Thus the company became an associate of Alembic Ltd.In September 20 2011 the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange. During 2012 Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine Pristiq. The company enters into a product development and license agreement with AccuBreak Pharmaceuticals Inc USA. During 2013 the company got USFDA approval for its NDA Desvenlafaxine Base Extended Release Tablets and also entered into an outlicensing agreement with Ranbaxy Pharmaceuticals Inc Ranbaxy to market its product in USA. During 2014 the company announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary Alembic Global Holding S.A..During 2015 the companys associate signs exclusive agreement with Novartis. During the year the company launched Aripiprazole on Day1. Also during the year the company transitioned to own marketing in the US.In 2016 the company formed 60:40 joint venture with Orbicular viz. Aleor Dermaceuitical Limited for developing Dermatology Products for international markets.In July 2017 Alembic Pharmaceuticals inaugurated a state of the art anticancer manufacturing facility at Panelav Halol Gujarat. The plant has an initial manufacturing capacity of 60 million tablets/capsules and approximate 20 million vials of liquid injectable and lyophilized concentrates. Alembic will commence exporting oncology products from the new plant to US Middle East North Africa Australia and South Africa. On 1 November 2017 Alembic Pharmaceuticals announced that through its 100 owned subsidiary Alembic Pharmaceuticals Inc. it has completed acquisition of West Caldwell New Jersey USA based generic drug developer Orit Laboratories LLC along with real estate owned by Okner Realty LLC. Orit has seven approved ANDAs and four ANDAs pending approval. With a stateoftheart 8600 square feet RD and pilot manufacturing facility Orit is focused on developing and filing oral solid and liquid products. Apart from existing ANDAs Orit adds complementary skill sets in soft gelatin based oral solids and oral liquids to Alembic with a team of eight highly experienced scientists. On 21 March 2018 Alembic Pharmaceuticals announced that the United States Food and Drug Administration US FDA conducted an inspection at the companys formulation facility located at Panelav Gujarat from 12 March to 20 March 2018. This was a scheduled inspection and at the end of the inspection the US FDA issued a Form 483 with 3 observations. None of the observations are related to data integrity or repetitive in nature. The company is preparing the response to the observations which will be submitted to the US FDA shortly. On 24 April 2018 Alembic Pharmaceuticals announced that the United States Food and Drug Administration US FDA conducted an inspection at Alembic Pharmaceuticals API Facility located at Panelav from 16 April 2018 to 23 April 2018. This was a scheduled inspection and at the end of the inspection there were zero 483s.In 2019 the Company launched 9 new products in the US.In 2021 Rhizens outlicenced novel molecule Umbralicib UKONIQ was launched by TG Therapeutics USA. During the year 202122 the Company acquired the balance 40 stake held by the joint venture partner in Aleor DermaceuticalsLimited Aleor and pursuant to said acquisition Aleor became a wholly owned subsidiary of the Company.The Board of Directors at their meeting held on 29th March 2022 approved the Scheme of Arrangement for Amalgamation of Aleor Dermaceuticals Limited wholly owned subsidiary with the Company and their respective shareholders with the Appointed Date 1st April 2021 which is now effective from 29th August 2022.

Alembic Pharmaceuticals Ltd Share Price: ₹489.65 per share as on 23 Mar, 2023 04:01 PM
Alembic Pharmaceuticals Ltd Market Capitalisation: ₹10,519.08Cr as of today
Alembic Pharmaceuticals Ltd Revenue: ₹1,509.46Cr as on December 2022 (Q4 22)
Alembic Pharmaceuticals Ltd Net Profit: ₹121.92Cr as on December 2022 (Q4 22)
Alembic Pharmaceuticals Ltd Listing date: 11 May, 2008
Alembic Pharmaceuticals Ltd Chairperson Name: Chirayu R Amin